Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
SHELTON, Conn., Sept. 2, 2025 /PRNewswire/ — Intensity Therapeutics, Inc. (Nasdaq: INTS) (“Intensity” or “the Company”), a late-stage... Read more.
The Bible is Back: Explosive Documentary Details How Christian Parents Are Reclaiming Education Hours — and Critics Can’t Stand It
‘Off School Property: Solving the Separation of Church and State’ explores chaos, collapse and a comeback for religious instruction; Little-known SCOTUS... Read more.
Inflammatix Data in Journal of Clinical Microbiology Validate Accuracy, Robustness, and Ease of Use of TriVerity™ Test System
Publication demonstrates superior analytical performance of TriVerity in assessing patients with suspected acute infection or sepsis SUNNYVALE, Calif., Sept. 2,... Read more.
Magaya and Adelante SCM Publish Future-Focused Preparedness Report: Freight Forwarding at a Crossroads: Preparing for 2026 and Beyond
New research illuminates widening gaps in AI readiness, technology investment, and customer satisfaction, making a fresh strategic approach essential. MIAMI, Sept.... Read more.
TERREPOWER’s Solar Brand Ontility to Showcase Sustainable Manufacturing at Scale at RE+, North America’s Largest Clean Energy Event
DAPHNE, Ala., Sept. 2, 2025 /PRNewswire/ — TERREPOWER, formerly BBB Industries, a global pure-play aftermarket leader in sustainable manufacturing, will showcase... Read more.
EyeCool Therapeutics Appoints Dr. Vance Thompson to Board of Directors
–Company Establishes Medical Advisory Board with World Renowned Ophthalmologists in Anterior Segment Field– CAMBRIDGE, Mass., Sept. 2, 2025 /PRNewswire/... Read more.
BitMine Immersion (BMNR) Announces Release of August Investor Presentation and Latest Video Message from Tom Lee, Chairman
BMNR investor presentation walks you through “the Alchemy of 5%” BitMine Crypto + Cash Holdings of $8.98 billion, including 1.87 million ETH Tokens BitMine... Read more.
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
JERUSALEM, Sept. 2, 2025 /PRNewswire/ — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (“Scinai”, or the “Company”), a biopharmaceutical... Read more.
Dario Secures Five New Employer Contracts Across Cardiometabolic Suite Including its Largest Employer to Date, Contributing to Annual Recurring Revenues Beginning Q3 2025
New customer launches representing 107,000 lives covered reinforce Dario’s B2B2C momentum and recurring revenue growth Dario’s multi-condition digital... Read more.
Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
PRINCETON, N.J., Sept. 2, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on... Read more.